Evogene Ltd. (NASDAQ:EVGN) Shares Shorted: Short Interest Down 93.2% in October

Evogene Ltd. (NASDAQ:EVGN) was the recipient of a large decline in short interest in October. As of October 15th, there was short interest totaling 63,883 shares, a decline of 93.2% from the September 30th total of 932,725 shares. Approximately 0.8% of the shares of the company are short sold. Based on an average daily volume of 244,058 shares, the days-to-cover ratio is currently 0.3 days.

Evogene Stock Down 3.8%

Shares of EVGN traded down $0.01 during midday trading on Tuesday, reaching $0.36. The company had a trading volume of 5,203 shares, compared to its average volume of 1,105,646. Evogene has a 1-year low of $0.35 and a 1-year high of $1.33. The firm has a 50 day simple moving average of $0.47 and a 200-day simple moving average of $0.68. The stock has a market cap of $3.10 million, a PE ratio of -0.39 and a beta of 1.44.

Insider Buying and Selling at Evogene

In other news, Director Leon Recanati acquired 460,000 shares of the business’s stock in a transaction on Tuesday, August 11th. The stock was bought at an average price of $0.64 per share, with a total value of $294,400.00. Following the completion of the acquisition, the director owned 1,343,886 shares of the company’s stock, valued at approximately $860,087.04. This represents a 52.04% increase in their ownership of the stock. The acquisition was disclosed in a document filed with the SEC, which is accessible through the SEC website. 7.40% of the stock is currently owned by company insiders.

Wall Street Analyst Weigh In

Separately, Weiss Ratings reaffirmed a “sell (e+)” rating on shares of Evogene in a research note on Friday, October 2nd. One investment analyst has rated the stock with a Sell rating. According to MarketBeat.com, the company presently has an average rating of “Sell”.

Evogene Company Profile

Evogene Ltd. is an Israel-based computational biology company that develops products and technologies for the life sciences and agriculture industries. Founded in 1999 and headquartered in Rehovot, Israel, the company uses its Computational Predictive Biology platform, which combines biological data, artificial intelligence and machine-learning tools to identify and develop novel biological products.

Evogene’s activities have included agricultural solutions such as crop-protection products, bio-stimulants and microbiome-based technologies.